Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes | Zendy

Klaus K. Witte | Zendy; Michael Drozd | Zendy; Andrew MN Walker | Zendy; Peysh A. Patel | Zendy; Jessica Kearney | Zendy; Sally E. Chapman | Zendy; Robert J. Sapsford | Zendy; John Gierula | Zendy; Maria F. Paton | Zendy; Judith E. Lowry | Zendy; Mark T. Kearney | Zendy; Richard M. Cubbon | Zendy

Open Access

Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes

Author(s) -

Klaus K. Witte,

Michael Drozd,

Andrew MN Walker,

Peysh A. Patel,

Jessica Kearney,

Sally E. Chapman,

Robert J. Sapsford,

John Gierula,

Maria F. Paton,

Judith E. Lowry,

Mark T. Kearney,

Richard M. Cubbon

Publication year - 2017

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc17-1406

Subject(s) - medicine , diabetes mellitus , heart failure , ramipril , ejection fraction , bisoprolol , cardiology , proportional hazards model , type 2 diabetes , endocrinology , blood pressure

Diabetes increases mortality in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction. Studies have questioned the safety of β-adrenoceptor blockers (β-blockers) in some patients with diabetes and reduced left ventricular ejection fraction. We examined whether β-blockers and ACE inhibitors (ACEIs) are associated with differential effects on mortality in CHF patients with and without diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research